Episode Synopsis "Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials "

Host: Sagar Lonial, MD, FACP Guest: Caitlin Costello, MD "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.

Listen "Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials "

More episodes of the podcast Global Oncology Academy

• ATTR Amyloidosis: Familial Vs Wild-Type
• ATTRv-PN: A Complicated Disease With a Poor Prognosis
• The Multiple Faces of ATTRv-PN
• Raising the Red Flag: What's Your Index of Suspicion for ATTRv-PN?
• Diagnosing ATTRv-PN: What's in Your Toolbox?
• Shh…Gene-Silencing Therapies for ATTRv-PN
• ATTRv-PN: A Family Affair?
• Advancing the Treatment of ATTRv-PN: What's in the Pipeline?
• Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review
• A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events
• Clinical Challenges With Triple-Class or Penta-Refractory MM
• Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
• The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies
• Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials
• Efficacy Data for Bispecific Antibodies in RRMM
• Preventing CRS and Neurotoxicities Related to Bispecific Antibodies
• Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies
• Considerations for Dosing Bispecific Antibodies
• Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization
• Integrating Bispecific Antibodies Into Clinical Practice
• Balancing the Scales: The Complementary Roles of RCTs and RWE in Modern Healthcare
• Distinguishing Between High- and Low-Quality RWE: A Journal Club for the Real World
• RWE Supporting CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer
• Unlocking Insights for Underrepresented Patients: The Role of Real-World Evidence in Addressing Limitations of CDK4/6 Inhibitor RCTs
• Importance of the Patient Perspective on RWE in Formulating SDM Conversations
• Real World Use of RWE in HR+ Metastatic Breast Cancer: The Oncologist Perspective
• Real World Evidence To Expand Knowledge of CDK4/6 Inhibitor-Related Adverse Effects
• Revolutionary Approaches to Improving Outcomes in Unresected LA SCCHN
• Keeping Pace in Hematologic Malignancies: 2023 Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes
• HER2-Directed ADCs in Breast Cancer